The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
ATAI Life Sciences, a biotech platform focused on psychedelics and other therapies for mental health, raised $225 million by offering 15 million shares at $15, the high end of the range of $13 to $15. The company offered 0.7 million more shares than anticipated....read more
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
ATAI Life Sciences, a biotech platform focused on psychedelics and underused therapies for psychiatric disorders, announced terms for its IPO on Friday.
The Berlin, Germany-based company plans to raise $200 million by offering 14.3 million shares at a price...read more
US IPO Weekly Recap: IPO market in full swing as biotechs lead a 16 IPO week
The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
German psychedelics startup ATAI Life Sciences prices upsized US IPO at $15 high end
ATAI Life Sciences, a biotech platform focused on psychedelics and other therapies for mental health, raised $225 million by offering 15 million shares at $15, the high end of the range of $13 to $15. The company offered 0.7 million more shares than anticipated....read more
US IPO Week Ahead: Biotechs and software lead a 15 IPO week
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
German psychedelics startup ATAI Life Sciences sets terms for $200 million US IPO
ATAI Life Sciences, a biotech platform focused on psychedelics and underused therapies for psychiatric disorders, announced terms for its IPO on Friday. The Berlin, Germany-based company plans to raise $200 million by offering 14.3 million shares at a price...read more